Citigroup’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-61,800
Closed -$634K 7100
2020
Q4
$634K Sell
61,800
-5,200
-8% -$52.7K ﹤0.01% 3993
2020
Q3
$676K Sell
67,000
-57,100
-46% -$581K ﹤0.01% 3592
2020
Q2
$1.29M Sell
124,100
-2,700
-2% -$27.9K ﹤0.01% 3278
2020
Q1
$1.07M Sell
126,800
-32,200
-20% -$313K ﹤0.01% 3102
2019
Q4
$1.39M Buy
159,000
+58,600
+58% +$485K ﹤0.01% 3384
2019
Q3
$1.08M Buy
100,400
+70,100
+231% +$757K ﹤0.01% 3555
2019
Q2
$385K Buy
30,300
+12,600
+71% +$290K ﹤0.01% 4678
2019
Q1
$687K Sell
17,700
-18,800
-52% -$574K ﹤0.01% 3824
2018
Q4
$743K Buy
36,500
+25,900
+244% +$777K ﹤0.01% 3702
2018
Q3
$486K Sell
10,600
-2,700
-20% -$130K ﹤0.01% 4313
2018
Q2
$787K Buy
13,300
+8,300
+166% +$481K ﹤0.01% 3615
2018
Q1
$340K Sell
5,000
-16,600
-77% -$1.24M ﹤0.01% 4396
2017
Q4
$2.13M Buy
21,600
+200
+0.9% +$22.4K ﹤0.01% 2609
2017
Q3
$2.56M Sell
21,400
-3,700
-15% -$344K ﹤0.01% 2400
2017
Q2
$2.19M Buy
25,100
+12,900
+106% +$722K ﹤0.01% 2495
2017
Q1
$454K Sell
12,200
-10,100
-45% -$369K ﹤0.01% 3950
2016
Q4
$685K Buy
22,300
+12,900
+137% +$558K ﹤0.01% 4053
2016
Q3
$630K Buy
9,400
+7,200
+327% +$364K ﹤0.01% 3681
2016
Q2
$66K Sell
2,200
-2,000
-48% -$62.5K ﹤0.01% 5392
2016
Q1
$123K Sell
4,200
-13,500
-76% -$610K ﹤0.01% 5514
2015
Q4
$1.39M Buy
17,700
+14,000
+378% +$1.1M ﹤0.01% 2789
2015
Q3
$279K Buy
+3,700
New +$350K ﹤0.01% 4249

Other funds holding PBYI

Citigroup's PBYI Position: Q2 2026 in Review

Citigroup increased its Puma Biotechnology (PBYI) stake by 533% in Q2 2026, buying an estimated $134K and bringing the position to 21,666 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #4407.

Citigroup first reported a position in PBYI in Q3 2013 and has held it in 50 quarters since. The position peaked at $6.77M in Q4 2017. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Citigroup held 21,666 shares of Puma Biotechnology worth $176K as of Q2 2026.
  • Citigroup bought 18,244 Puma Biotechnology shares in Q2 2026, an estimated $134K.
  • Puma Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4407 holding.
  • Citigroup first reported a position in Puma Biotechnology in Q3 2013 and has held it in 50 quarters since.
  • Citigroup's Puma Biotechnology position peaked at $6.77M in Q4 2017.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.